22.30
+0.20
(0.90%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 21.41 - 22.36 |
| 52 week | 4.82 - 22.49 |
| Open | 22.30 |
| Vol / Avg. | 1.85M/1.38M |
| Mkt cap | 1.45B |
| P/E | 44.51 |
| Div/yield | - |
| EPS | 0.50 |
| Shares | 64.93M |
| Beta | 1.31 |
| Inst. own | 62% |
Events
Aug 5, 2013
Q2 2013 Santarus Inc. Earnings Release
Jun 11, 2013
Santarus Inc. Annual Shareholder Meeting
- 4:00PM EDT -
Jun 3, 2013
Santarus Inc. at Jefferies Global Healthcare Conference
- 3:00PM EDT -
May 30, 2013
Santarus Inc. at Deutsche Bank dbAccess Health Care Conference
- 8:40AM EDT -
May 16, 2013
Santarus Inc. at Bank of America Merrill Lynch Health Care Conference
May 8, 2013
Q1 2013 Santarus Inc. Earnings Release
May 6, 2013
Q1 2013 Santarus Inc. Earnings Conference Call
Mar 19, 2013
Santarus Inc. at Roth Conference
Mar 6, 2013
Santarus Inc. at Cowen Health Care Conference
Mar 4, 2013
Q4 2012 Santarus Inc. Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 23.56% | 8.51% |
| Operating margin | 25.01% | 9.26% |
| EBITD margin | - | 12.07% |
| Return on average assets | 42.42% | 13.36% |
| Return on average equity | 79.01% | 27.89% |
| Employees | 290 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 400, 3611 Valley Centre Drive
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-3145700 (Phone)
+1-858-3145701 (Fax)
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-3145700 (Phone)
+1-858-3145701 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company�s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company�s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody).
Officers and directors
| David F. Hale | Independent Chairman of the Board | |
| Gerald T. Proehl | President, Chief Executive Officer, Director | |
| Debra P. Crawford | Chief Financial Officer, Senior Vice President, Treasurer, Secretary | |
| Wendell Wierenga Ph.D. | Executive Vice President - Research and Development | |
| Carey J. Fox J.D. | Senior Vice President, General Counsel | |
| Julie A. DeMeules | Senior Vice President - Human Resources | |
| E. David Ballard II, M.D. | Senior Vice President - Medical Affairs and Pharmacovigilance | |
| Maria Bedoya-Toro Ph.D. | Senior Vice President - Regulatory Affairs and Quality Assurance | |
| William C. Denby III | Senior Vice President - Commercial Operations | |
| Warren E. Hall | Senior Vice President - Manufacturing and Product Development |
